The Food and Drug Administration is considering authorizing Pfizer’s COVID-19 vaccine in children under five years of age. The U.S. could begin rolling out the shots as early as Feb. 21. (Reuters)

Public health officials at the Centers for Disease Control and Prevention are weighing changes to the agency’s metrics for lifting COVID-19 restrictions. The agency is debating whether it should use case rates or hospitalization data to make future decisions on restrictions. (Politico)

As the demand for COVID-19 vaccines and testing declines, CVS Health will likely face a decline in sales, CFO Shawn Guertin said. The company will continue its push to reposition itself as a healthcare destination. (CNBC Weekly)

MaaT Pharma and Skyepharma are partnering to build a new manufacturing facility for microbiome-based therapies, including MaaT’s Graft-versus-Host disease (GvHD) candidate. The facility could significantly bolster MaaT’s output in the next decade. (Endpoints News)

As digital pharmacies face growing competition, startups Thirty Madison and Nurx announced plans to merge. Thirty Madison, which provides care for individuals with allergies and migraines, hopes to expand its list of conditions in 2022. (STAT)